Collections Top Papers for 2020 - Radiatio...

Top Papers for 2020 - Radiation Oncology
Charles B Simone, Jeffrey A Bogart, Alvin R Cabrera, Megan E Daly, Nicholas J DeNunzio, Frank Detterbeck, Corinne Faivre-Finn, Nancy Gatschet, Elizabeth Gore, Salma K Jabbour, Tim J Kruser, Bryan J Schneider, Ben Slotman, Andrew Turrisi, Abraham J Wu, Jing Zeng, Kenneth E Rosenzweig
PURPOSE: Several sentinel phase III randomized trials have recently been published challenging traditional radiation therapy (RT) practices for small cell lung cancer (SCLC). This American Society for Radiation Oncology guideline reviews the evidence for thoracic RT and prophylactic cranial irradiation (PCI) for both limited-stage (LS) and extensive-stage (ES) SCLC. METHODS: The American Society for Radiation Oncology convened a task force to address 4 key questions focused on indications, dose fractionation, techniques and timing of thoracic RT for LS-SCLC, the role of stereotactic body radiation therapy (SBRT) compared with conventional RT in stage I or II node negative SCLC, PCI for LS-SCLC and ES-SCLC, and thoracic consolidation for ES-SCLC...
May 2020: Practical Radiation Oncology
Aaron C Tan, David M Ashley, Giselle Y López, Michael Malinzak, Henry S Friedman, Mustafa Khasraw
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. There is a slight predominance in males, and incidence increases with age. The standard approach to therapy in the newly diagnosed setting includes surgery followed by concurrent radiotherapy with temozolomide and further adjuvant temozolomide. Tumor-treating fields, delivering low-intensity alternating electric fields, can also be given concurrently with adjuvant temozolomide...
June 1, 2020: CA: a Cancer Journal for Clinicians
Adrian Murray Brunt, Joanne S Haviland, Mark Sydenham, Rajiv K Agrawal, Hafiz Algurafi, Abdulla Alhasso, Peter Barrett-Lee, Peter Bliss, David Bloomfield, Joanna Bowen, Ellen Donovan, Andy Goodman, Adrian Harnett, Martin Hogg, Sri Kumar, Helen Passant, Mary Quigley, Liz Sherwin, Alan Stewart, Isabel Syndikus, Jean Tremlett, Yat Tsang, Karen Venables, Duncan Wheatley, Judith M Bliss, John R Yarnold
PURPOSE: Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and disease outcomes after 5-fr regimens. Ten-year results are presented. METHODS: Women ≥ 50 years of age with low-risk invasive breast carcinoma (pT1-2 pN0) were randomly assigned to 50 Gy/25 fr (5 weeks) or 30 or 28.5 Gy in 5 once-weekly fr of 6...
October 1, 2020: Journal of Clinical Oncology
Matthias Guckenberger, Yolande Lievens, Angelique B Bouma, Laurence Collette, Andre Dekker, Nandita M deSouza, Anne-Marie C Dingemans, Beatrice Fournier, Coen Hurkmans, Frédéric E Lecouvet, Icro Meattini, Alejandra Méndez Romero, Umberto Ricardi, Nicola S Russell, Daniel H Schanne, Marta Scorsetti, Bertrand Tombal, Dirk Verellen, Christine Verfaillie, Piet Ost
Oligometastatic disease has been proposed as an intermediate state between localised and systemically metastasised disease. In the absence of randomised phase 3 trials, early clinical studies show improved survival when radical local therapy is added to standard systemic therapy for oligometastatic disease. However, since no biomarker for the identification of patients with true oligometastatic disease is clinically available, the diagnosis of oligometastatic disease is based solely on imaging findings. A small number of metastases on imaging could represent different clinical scenarios, which are associated with different prognoses and might require different treatment strategies...
January 2020: Lancet Oncology
Yolande Lievens, Matthias Guckenberger, Daniel Gomez, Morten Hoyer, Puneeth Iyengar, Isabelle Kindts, Alejandra Méndez Romero, Daan Nevens, David Palma, Catherine Park, Umberto Ricardi, Marta Scorsetti, James Yu, Wendy A Woodward
BACKGROUND: Recognizing the rapidly increasing interest and evidence in using metastasis-directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO convened a committee to establish consensus regarding definitions of OMD and define gaps in current evidence. METHODS: A systematic literature review focused on curative intent MDRT was performed in Medline, Embase and Cochrane. Subsequent consensus opinion, using a Delphi process, highlighted the current state of evidence and the limitations in the available literature...
July 2020: Radiotherapy and Oncology
William A Hall, Eric Paulson, Brian J Davis, Daniel E Spratt, Todd M Morgan, David Dearnaley, Alison C Tree, Jason A Efstathiou, Mukesh Harisinghani, Ashesh B Jani, Mark K Buyyounouski, Thomas M Pisansky, Phuoc T Tran, R Jeffrey Karnes, Ronald C Chen, Fabio L Cury, Jeff M Michalski, Seth A Rosenthal, Bridget F Koontz, Anthony C Wong, Paul L Nguyen, Thomas A Hope, Felix Feng, Howard M Sandler, Colleen A F Lawton
PURPOSE: In 2009, the Radiation Therapy Oncology Group (RTOG) genitourinary members published a consensus atlas for contouring prostate pelvic nodal clinical target volumes (CTVs). Data have emerged further informing nodal recurrence patterns. The objective of this study is to provide an updated prostate pelvic nodal consensus atlas. METHODS AND MATERIALS: A literature review was performed abstracting data on nodal recurrence patterns. Data were presented to a panel of international experts, including radiation oncologists, radiologists, and urologists...
January 1, 2021: International Journal of Radiation Oncology, Biology, Physics
Gaurav Dhawan, Rachna Kapoor, Rajiv Dhawan, Ravinder Singh, Bharat Monga, James Giordano, Edward J Calabrese
The new coronavirus COVID-19 disease caused by SARS-CoV-2 was declared a global public health emergency by WHO on Jan 30, 2020. Despite massive efforts from various governmental, health and medical organizations, the disease continues to spread globally with increasing fatality rates. Several experimental drugs have been approved by FDA with unknown efficacy and potential adverse effects. The exponentially spreading pandemic of COVID-19 deserves prime public health attention to evaluate yet unexplored arenas of management...
June 2020: Radiotherapy and Oncology
Eva Versteijne, Mustafa Suker, Karin Groothuis, Janine M Akkermans-Vogelaar, Marc G Besselink, Bert A Bonsing, Jeroen Buijsen, Olivier R Busch, Geert-Jan M Creemers, Ronald M van Dam, Ferry A L M Eskens, Sebastiaan Festen, Jan Willem B de Groot, Bas Groot Koerkamp, Ignace H de Hingh, Marjolein Y V Homs, Jeanin E van Hooft, Emile D Kerver, Saskia A C Luelmo, Karen J Neelis, Joost Nuyttens, Gabriel M R M Paardekooper, Gijs A Patijn, Maurice J C van der Sangen, Judith de Vos-Geelen, Johanna W Wilmink, Aeilko H Zwinderman, Cornelis J Punt, Casper H van Eijck, Geertjan van Tienhoven
PURPOSE: Preoperative chemoradiotherapy may improve the radical resection rate for resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven. PATIENTS AND METHODS: In this randomized phase III trial in 16 centers, patients with resectable or borderline resectable pancreatic cancer were randomly assigned to receive preoperative chemoradiotherapy, which consisted of 3 courses of gemcitabine, the second combined with 15 × 2.4 Gy radiotherapy, followed by surgery and 4 courses of adjuvant gemcitabine or to immediate surgery and 6 courses of adjuvant gemcitabine...
June 1, 2020: Journal of Clinical Oncology
Thomas B Brunner, Karin Haustermans, Florence Huguet, Alessio G Morganti, Somnath Mukherjee, Claus Belka, Robert Krempien, Maria A Hawkins, Vincenzo Valentini, Falk Roeder
Despite of the predominant role of chemotherapy and surgery in pancreatic ductal adenocarcinoma (PDAC), radiotherapy (RT) still has a place in multimodal management of this disease where local tumour sequelae are fatal in about 40% of the patients. RT (chemoradiotherapy and stereotactic body radiotherapy) is used and investigated in the non-metastatic setting as part of definitive treatment strategies, in (neo)adjuvant settings and for locally recurrent disease. The ACROP committee was delegated by ESTRO to recommend target volume delineation for these clinical situations...
January 2021: Radiotherapy and Oncology
Cecile Le Pechoux, Corinne Faivre-Finn, Sara Ramella, Fiona McDonald, Farkhad Manapov, Paul Martin Putora, Ben Slotman, Dirk De Ruysscher, Umberto Ricardi, Xavier Geets, José Belderbos, Christoph Pöttgen, Rafal Dziadiuszko, Stephanie Peeters, Yolande Lievens, Coen Hurkmans, Paul Van Houtte, Ursula Nestle
Radiotherapy (RT) plays a major role in the treatment of small cell lung cancer (SCLC). Therefore, the ACROP committee was asked by ESTRO to provide recommendations on target volume delineation for standard clinical scenarios in definitive (chemo)-radiotherapy (CRT), adjuvant RT for stages I-III SCLC and consolidation thoracic RT for stage IV disease. The aim of these guidelines is to standardise and optimise the process of RT treatment planning for clinical practice and prospective studies. The process for the development of the guidelines included the evaluation of a structured questionnaire followed by a consensus discussion, voting and writing process within the committee...
November 2020: Radiotherapy and Oncology
Raj Singh, Eric J Lehrer, Basem Dahshan, Joshua D Palmer, Arjun Sahgal, Peter C Gerszten, Nicholas G Zaorsky, Daniel M Trifiletti
BACKGROUND AND PURPOSE: To perform a systematic review/meta-analysis of outcomes for patients with spinal metastases treated with stereotactic radiosurgery (SRS) (either single-fraction (SF-SRS) or multiple-fraction (MF-SRS)) or conventional radiotherapy (RT). MATERIALS AND METHODS: Thirty-seven studies were identified. Primary outcomes were 1-year local control (LC) and acute/late grade 3-5 toxicities (including vertebral compression fractures (VCF)). Weighted random effects meta-analyses using the DerSimonian and Laird methods and meta-regressions were conducted to characterize and compare effect sizes...
May 2020: Radiotherapy and Oncology
Andrew Wirth, N George Mikhaeel, Berthe M P Aleman, Chelsea C Pinnix, Louis S Constine, Umberto Ricardi, Tim M Illidge, Hans Theodor Eich, Bradford S Hoppe, Bouthaina Dabaja, Andrea K Ng, Youlia Kirova, Anne Kiil Berthelsen, Karin Dieckmann, Joachim Yahalom, Lena Specht
Involved node radiation therapy for lymphoma was introduced with the aim of using the smallest effective treatment volume, individualized to the patient's disease distribution, to avoid the potentially unnecessary normal tissue exposure and toxicity risks associated with traditional involved field radiation therapy. The successful implementation of involved node radiation therapy requires optimal imaging and precise coregistration of baseline imaging with the radiation therapy planning computed tomography scan...
August 1, 2020: International Journal of Radiation Oncology, Biology, Physics
Kenneth Jensen, Jeppe Friborg, Christian Rønn Hansen, Eva Samsøe, Jørgen Johansen, Maria Andersen, Bob Smulders, Elo Andersen, Martin Skovmos Nielsen, Jesper Grau Eriksen, Jørgen Breede Baltzer Petersen, Ulrik Vindelev Elstrøm, Anne Ivalu Holm, Mohammed Farhadi, Morten Hjartdal Morthorst, Peter Sandegaard Skyt, Jens Overgaard, Cai Grau
No abstract text is available yet for this article.
October 2020: Radiotherapy and Oncology
Vaibhav G Patel, William K Oh, Matthew D Galsky
Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades, the systemic management of muscle-invasive and advanced bladder cancer has primarily consisted of platinum-based chemotherapy. Over the past 10 years, innovations in sequencing technologies have led to rapid genomic characterization of bladder cancer, deepening our understanding of bladder cancer pathogenesis and exposing potential therapeutic vulnerabilities. On the basis of its high mutational burden, immune checkpoint inhibitors were investigated in advanced bladder cancer, revealing durable responses in a subset of patients...
September 2020: CA: a Cancer Journal for Clinicians
Andrea Riccardo Filippi, Elvio Russi, Stefano Maria Magrini, Renzo Corvò
No abstract text is available yet for this article.
July 1, 2020: International Journal of Radiation Oncology, Biology, Physics
Romaana Mir, Sarah M Kelly, Ying Xiao, Alisha Moore, Catharine H Clark, Enrico Clementel, Coreen Corning, Martin Ebert, Peter Hoskin, Coen W Hurkmans, Satoshi Ishikura, Ingrid Kristensen, Stephen F Kry, Joerg Lehmann, Jeff M Michalski, Angelo F Monti, Mitsuhiro Nakamura, Kenton Thompson, Huiqi Yang, Eduardo Zubizarreta, Nicolaus Andratschke, Elizabeth Miles
BACKGROUND AND PURPOSE: The Global Quality Assurance of Radiation Therapy Clinical Trials Harmonization Group (GHG) is a collaborative group of Radiation Therapy Quality Assurance (RTQA) Groups harmonizing and improving RTQA for multi-institutional clinical trials. The objective of the GHG OAR Working Group was to unify OAR contouring guidance across RTQA groups by compiling a single reference list of OARs in line with AAPM TG 263 and ASTRO, together with peer-reviewed, anatomically defined contouring guidance for integration into clinical trial protocols independent of the radiation therapy delivery technique...
September 2020: Radiotherapy and Oncology
Paolo Sogono, Mathias Bressel, Steven David, Mark Shaw, Sarat Chander, Julie Chu, Nikki Plumridge, Keelan Byrne, Nicholas Hardcastle, Tomas Kron, Greg Wheeler, Gerard G Hanna, Michael MacManus, David Ball, Shankar Siva
PURPOSE: Fewer attendances for radiation therapy results in increased efficiency and less foot traffic within a radiation therapy department. We investigated outcomes after single-fraction (SF) stereotactic body radiation therapy (SBRT) in patients with oligometastatic disease. METHODS AND MATERIALS: Between February 2010 and June 2019, patients who received SF SBRT to 1 to 5 sites of oligometastatic disease were included in this retrospective study. The primary objective was to describe patterns of first failure after SBRT...
March 1, 2021: International Journal of Radiation Oncology, Biology, Physics
Manish A Shah, Erin B Kennedy, Daniel V Catenacci, Dana C Deighton, Karyn A Goodman, Narinder K Malhotra, Christopher Willett, Brendon Stiles, Prateek Sharma, Laura Tang, Bas P L Wijnhoven, Wayne L Hofstetter
PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with locally advanced esophageal cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the more recently published literature (1999-2019) on therapy options for patients with locally advanced esophageal cancer and provide recommended care options for this patient population. RESULTS: Seventeen randomized controlled trials met the inclusion criteria...
August 10, 2020: Journal of Clinical Oncology
William Small, Walter R Bosch, Mathew M Harkenrider, Jonathan B Strauss, Nadeem Abu-Rustum, Kevin V Albuquerque, Sushil Beriwal, Carien L Creutzberg, Patricia J Eifel, Beth A Erickson, Anthony W Fyles, Courtney L Hentz, Anuja Jhingran, Ann H Klopp, Charles A Kunos, Loren K Mell, Lorraine Portelance, Melanie E Powell, Akila N Viswanathan, Joseph H Yacoub, Catheryn M Yashar, Kathryn A Winter, David K Gaffney
PURPOSE: Accurate target definition is critical for the appropriate application of radiation therapy. In 2008, the Radiation Therapy Oncology Group (RTOG) published an international collaborative atlas to define the clinical target volume (CTV) for intensity modulated pelvic radiation therapy in the postoperative treatment of endometrial and cervical cancer. The current project is an updated consensus of CTV definitions, with removal of all references to bony landmarks and inclusion of the para-aortic and inferior obturator nodal regions...
February 1, 2021: International Journal of Radiation Oncology, Biology, Physics
Allison E Garda, Patrick J Navin, Kenneth W Merrell, James A Martenson, Michelle A Neben Wittich, Michael G Haddock, Terence T Sio, William G Rule, Jonathan B Ashman, Shannon P Sheedy, Christopher L Hallemeier
PURPOSE: Optimal clinical target volume (CTV) for inguinal lymph node irradiation in anal cancer remains uncertain. This study documents the location of radiographically involved inguinal lymph nodes and proposes guidelines for CTV delineation. MATERIALS AND METHODS: Patients with anal canal squamous cell carcinoma with inguinal lymph node metastases were identified. Criteria for lymph node involvement included: >15 mm short axis or suspicious morphology on CT or MRI, increased avidity on 18-FDG-PET, or positive biopsy...
August 2020: Radiotherapy and Oncology
2020-12-17 20:50:53
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"